OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER
Objectives: Single agent intravenous Topotecan is an effective treatment for small cell lung cancer /SCLC/ after failure of first- line chemotherapy. The aim of this study was to evaluate the efficacy and toxicity of intravenous Topotecan in recurrent SCCC. Methods: In the period 2008- 2009 seventee...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Peytchinski Publishing,
2010-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_92e49ad2bcb04b88bffea317d692c2d0 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Deyan Davidov |e author |
| 245 | 0 | 0 | |a OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER |
| 260 | |b Peytchinski Publishing, |c 2010-11-01T00:00:00Z. | ||
| 500 | |a 10.5272/jimab.1632010_70 | ||
| 500 | |a 1312-773X | ||
| 520 | |a Objectives: Single agent intravenous Topotecan is an effective treatment for small cell lung cancer /SCLC/ after failure of first- line chemotherapy. The aim of this study was to evaluate the efficacy and toxicity of intravenous Topotecan in recurrent SCCC. Methods: In the period 2008- 2009 seventeen consecutive patients with relapsed SCLC entered the study. The treatment schedule consists of Topotecan 1,5 mg/m2 i.v. for five consecutive days, with repetition every 21 days. Results: Overall response rate was 23,5%. Median survival was 6,4 months. Nausea, vomiting and neutropenia were most common side effects. Conclusion: Intravenous Topotecan is effective as second- line therapy for patients with relapsed SCCC with good tolerability. | ||
| 546 | |a EN | ||
| 690 | |a Relapsed small cell lung cancer | ||
| 690 | |a Second- line treatment | ||
| 690 | |a Intravenous Topotecan | ||
| 690 | |a Survival | ||
| 690 | |a Dentistry | ||
| 690 | |a RK1-715 | ||
| 690 | |a Medicine (General) | ||
| 690 | |a R5-920 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Journal of IMAB, Vol 16, Iss 3, Pp 70-73 (2010) | |
| 787 | 0 | |n http://www.journal-imab-bg.org/statii-10/vol16_b3_p70-73.pdf | |
| 787 | 0 | |n https://doaj.org/toc/1312-773X | |
| 856 | 4 | 1 | |u https://doaj.org/article/92e49ad2bcb04b88bffea317d692c2d0 |z Connect to this object online. |